• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

NOACs Now Mainstream for the Use of Anticoagulation in Non-Valvular Atrial Fibrillation in Australia
The management of stroke risk in patients with non-valvular atrial fibrillation has changed over the past few years. This change has occurred due to the introduction of novel oral anticoagulants (NOACs) such as apixaban, rivaroxaban and dabigatran for the management of non-valvular atrial fibrillation. These agents have shown comparable stroke risk reduction to warfarin in large international multicentre trials [1 –3]. This has changed the clinical practice of many treating physicians since their introduction from 2011 to 2013.
Source: Heart, Lung and Circulation - March 22, 2018 Category: Cardiology Authors: Derk Pol, Claire Curtis, Satish Ramukumar, Logan Bittinger Tags: Brief Communication Source Type: research

Epidemiology of atrial fibrillation
ConclusionsAlthough the prevalence of AF worldwide is increasing steadily, large variation can be seen between studies and countries. Further epidemiological studies should be undertaken globally, especially in Asian and African countries so that a better and more accurate picture of the incidence and prevalence of AF can be captured, to enable stroke prevention strategies to be appropriately implemented to prevent or reduce the risk of stroke, the most severe consequence of AF.
Source: International Journal of Clinical Practice - March 1, 2018 Category: Internal Medicine Authors: Hanis Zulkifly, Gregory Y. H. Lip, Deirdre A. Lane Tags: PERSPECTIVE Source Type: research

The impact of non-vitamin K antagonist oral anticoagulants (NOACs) on anticoagulation therapy in rural Australia.
CONCLUSIONS: In rural WA, about one-third of patients with an indication for anticoagulation therapy receive NOACs, but one-third of patients with AF and at risk of stroke received no anticoagulant therapy, and may benefit from NOAC therapy. PMID: 29320668 [PubMed - in process]
Source: Medical Journal of Australia - January 11, 2018 Category: General Medicine Tags: Med J Aust Source Type: research

Dedicated warfarin care programme results in superior warfarin control in Queensland, Australia
ConclusionAustralian warfarin control was good when managed by either GP or WCP, but WCP management increased TTR by 13%. Dedicated warfarin programmes can improve warfarin control and optimise therapy for patients.
Source: International Journal of Clinical Practice - January 9, 2018 Category: Internal Medicine Authors: Nijole Bernaitis, Tony Badrick, Shailendra Anoopkumar ‐Dukie Tags: ORIGINAL PAPER Source Type: research

Anticoagulation knowledge in patients with atrial fibrillation: An Australian survey
ConclusionThe study identified knowledge gaps in patients taking OACs, and these deficiencies appeared to be greater in participants taking DOACs. Knowledge assessment should be integrated into patient counselling sessions to help identify and resolve knowledge deficits.
Source: International Journal of Clinical Practice - January 1, 2018 Category: Internal Medicine Authors: Kehinde O. Obamiro, Leanne Chalmers, Kenneth Lee, Bonnie J. Bereznicki, Luke R. E. Bereznicki Tags: ORIGINAL PAPER Source Type: research

Bleeding-related admissions in patients with atrial fibrillation receiving antithrombotic therapy: results from the Tasmanian Atrial Fibrillation (TAF) study
ConclusionThe overall rate of bleeding in this cohort was low relative to similar observational studies. The rate of major bleeding was higher in patients prescribed warfarin compared to DOACs, with a similar rate of major bleeding for DOACs and antiplatelet agents. Our findings suggest potential to strategies to reduce bleeding include using DOACs in preference to warfarin, and avoiding multiple antithrombotic therapies in patients with AF.
Source: European Journal of Clinical Pharmacology - September 22, 2017 Category: Drugs & Pharmacology Source Type: research

The representativeness of direct oral anticoagulant clinical trials to hospitalized patients with atrial fibrillation
ConclusionsThe apixaban and dabigatran trials may be the most representative of hospitalized patients with AF. The DOAC trial results can readily be extrapolated to, and guide prescribing for, at least two thirds of patients discharged from a large metropolitan health service in Australia.
Source: European Journal of Clinical Pharmacology - July 27, 2017 Category: Drugs & Pharmacology Source Type: research

Changes in Oral Anticoagulant Prescribing for Stroke Prevention in Patients with Atrial Fibrillation
This study aimed to compare anticoagulation practice in Australia during the pre- and post-direct oral anticoagulant (DOAC) eras. Between January 2011 and July 2015, patients with non-valvular AF (NVAF) admitted to the Royal Hobart Hospital, Tasmania, Australia, were retrospectively reviewed. The pre- and post-DOAC era cohorts included admissions from January 2011 to July 2013 and August 2013 to July 2015, respectively.
Source: The American Journal of Cardiology - July 14, 2017 Category: Cardiology Authors: Endalkachew Admassie, Leanne Chalmers, Luke R. Bereznicki Source Type: research

Combining Watchman left atrial appendage closure and catheter ablation for atrial fibrillation: multicentre registry results of feasibility and safety during implant and 30 days follow-up
ConclusionThe outcomes from these international, multicentre registries support the feasibility and safety of performing combined procedures of ablation and Watchman LAAC for patients with non-valvular AF and high stroke risk. Further data are needed on long-term outcomes for the hybrid technique on all-cause stroke and mortality.
Source: Europace - July 3, 2017 Category: Cardiology Source Type: research

Pages: 1  2  3  4  5